Following the emergency use authorization of the mRNA‐1273 vaccine on the 18^thof December 2020,two mRNA vaccines are in current use for the prevention of coronavirus disease 2019 (COVID‐19). For both mRNA vaccines, the phase IIIpivotal trials excluded individuals with a history of allergy to vaccine components.